An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Trial Profile

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs E 7820 (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 21 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 19 Apr 2016 Planned End Date changed from 1 Sep 2014 to 1 Dec 2016.
    • 30 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top